Abstract
AbstractA dysfunction of GABAergic neurotransmission is related to diseases such as epilepsy, Huntington‐disease and Parkinson‐syndrome. A new 18F‐fluorine labelled GABA transporter ligand for the GABA‐transporter subtype GAT‐3 was developed which may allow the in vivo visualisation of GABAergic neurotransmission. The precursors ethyl (2‐(4‐hydroxyphenyl)bis(4‐methoxyphenyl)‐methoxy)ethyl)‐piperidine‐3‐carboxylate and ethyl(2‐((4‐(2‐tosylethoxy)phenyl)‐bis(4‐methoxyphenyl)‐methoxy) ethyl)‐piperidine3‐carboxylate were synthesised and labelled by the use of 2‐[18F]fluoroethyltosylate or [18F]fluoride. Subsequent cleavage of the ester moiety gave the final product (±)‐(2‐((4‐(2‐[18F]fluoroethoxy)phenyl)bis(4‐methoxy‐phenyl)methoxy)ethyl)piperidine‐3‐carboxylic acid in a decay corrected yield of 33–36%. Preliminary biodistribution kinetics were determined with BALB/c mice ex vivo for brain, liver, kidney, spleen, blood and bone. (2‐((4‐(2‐[18F]fluoroethoxy)‐phenyl)bis(4‐methoxyphenyl)methoxy)‐ethyl) piperidine‐3‐carboxylic acid showed a maximum brain uptake after 1 h p.i. of about 0.3% ID/g. Copyright © 2001 John Wiley & Sons, Ltd.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Labelled Compounds and Radiopharmaceuticals
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
